ContraFect (ContraFect) Operating Cash Flow per Share : $-23.67 (TTM As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is ContraFect Operating Cash Flow per Share?

ContraFect's operating cash flow per share for the three months ended in Sep. 2023 was $-0.81. ContraFect's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-23.67.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 30.60% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 27.30% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 28.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for ContraFect's Operating Cash Flow per Share or its related term are showing as below:

CFRXQ' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 13.6 Med: 30.8 Max: 35.9
Current: 30.6

During the past 11 years, ContraFect's highest 3-Year average Operating Cash Flow per Share Growth Rate was 35.90% per year. The lowest was 13.60% per year. And the median was 30.80% per year.

CFRXQ's 3-Year OCF Growth Rate is ranked better than
79.21% of 1241 companies
in the Biotechnology industry
Industry Median: 3.7 vs CFRXQ: 30.60

ContraFect Operating Cash Flow per Share Historical Data

The historical data trend for ContraFect's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ContraFect Operating Cash Flow per Share Chart

ContraFect Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Operating Cash Flow per Share

Get a 7-Day Free Trial

-276.41

-263.73

-116.45

-89.40

-88.24

ContraFect Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-19.62	-16.31	-4.46	-2.09	-0.81

Competitive Comparison of ContraFect's Operating Cash Flow per Share

For the Biotechnology subindustry, ContraFect's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ContraFect's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ContraFect's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ContraFect's Price-to-Operating-Cash-Flow falls into.

ContraFect Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

ContraFect's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (A: Dec. 2022 )	=	Cash Flow from Operations (A: Dec. 2022 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2022 )
	=	-45.974	/	0.521
	=	-88.24

ContraFect's Operating Cash Flow per Share for the quarter that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (Q: Sep. 2023 )	=	Cash Flow from Operations (Q: Sep. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2023 )
	=	-8.669	/	10.705
	=	-0.81

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.67

ContraFect Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of ContraFect's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

ContraFect (ContraFect) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ContraFect Corp (OTCPK:CFRXQ) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701

Website

https://www.contrafect.com

ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.

Executives

Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Lishan Aklog	director	420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Michael Messinger	officer: VP Finance	238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534
Cary Sucoff	director	1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904
David N. Low	director	EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111
Sol J Barer	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Lisa Ricciardi	director	C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Joshua B Muntner	officer: SVP Business Development	30 FIFTH AVENUE, 12F, NEW YORK NY 10011
Shanghai Fosun Pharmaceutical (group) Co., Ltd.	10 percent owner	BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233
Fosun Industrial Co., Ltd	10 percent owner	FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000
Cara M Cassino	officer: Chief Medical Officer	757 STONY POINT ROAD, BENSON VT 05743
Natalie Bogdanos	officer: General Counsel	207-23 DARREN DRIVE, BAYSIDE NY 11360
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael J. Otto	director	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421